A new Quantitative Modeling and Simulators Framework to Support Applicant and Dosage Choice of Anti-SARS-CoV-2 Monoclonal antibodies to succeed Bamlanivimab in to a First-in-Human Clinical Trial.
https://www.selleckchem.com/products/leptomycinb.html